<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939274</url>
  </required_header>
  <id_info>
    <org_study_id>RSI-CLIPT-002</org_study_id>
    <nct_id>NCT02939274</nct_id>
  </id_info>
  <brief_title>An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (VisudyneÂ®) for the Treatment of Cutaneous Metastases of Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rogers Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rogers Sciences Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase II study is to evaluate the efficacy and safety of Continuous Low-
      Irradiance Photodynamic Therapy (CLIPT) when used with Verteporfin in the treatment of
      cutaneous metastases of breast cancer for which no curative or significantly palliative
      therapy exists, including chest wall therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Day 23</time_frame>
    <description>To evaluate the objective response rate (ORR=CR+PR) at Day 23 (3 weeks) after the initial treatment. The objective response rate is defined as the rate of complete response (CR) plus the rate of partial response (PR).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verteporfin</intervention_name>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Low-Irradiance Photodynamic Therapy (CLIPT)</intervention_name>
    <arm_group_label>Open Label</arm_group_label>
    <other_name>CLIPT Illumination System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed Stage IIIb or IV breast cancer with
             cutaneous metastases.

        Exclusion Criteria:

          -  Participants receiving any medications or substances that are known to cause
             photosensitivity (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea
             hypoglycemic agents, thiazide diuretics, griseofulvin, fluoroquinolones, St. Johns'
             wort, amiodarone) are ineligible.

          -  Participants who have received prior systemic therapy (chemotherapy or targeted
             therapy) within 7 days of Study Day 1 or those who have not recovered from clinically
             significant adverse events due to agents administered more than 7 days earlier.
             (continuation of the same regimen of HER-2 antibody targeted therapy agents, hormonal
             therapy and treatment with bisphosphonates or denosumab are permitted)

          -  Participants who are receiving any other investigational agents during the proposed
             treatment cycle.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Isakoff, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven J Isakoff, MD PhD</last_name>
    <phone>617 726 4920</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karleen Habin, RN</last_name>
    <phone>617 726 1922</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J Isakoff, MD PhD</last_name>
      <phone>617-726-4920</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Overmoyer, MD</last_name>
      <phone>617-632-3800</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

